KIT-exon-11 mutations in GISTs correlate with higher partial response rates and improved surgical outcomes with neoadjuvant Gleevec. Non-KIT exon 11 mutations and wild-type KIT/PDGFRA GISTs show less ...
Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patient The unconfirmed partial response (uPR) that was observed in the first scan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results